opioid receptor mu 1
آخر تحديث 6 Sept 2023
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
ال OPRM1 gene provides instructions for making a protein called the mu (μ) opioid receptor. Opioid receptors are part of the endogenous opioid system, which is the body's internal system for regulating pain, reward, and addictive behaviors. It consists of opioid substances produced naturally within the body (called endogenous opioids) and their receptors, into which opioids fit like keys into locks. Opioid receptors are found in the nervous system, where they are embedded in the outer membrane of nerve cells (neurons). When opioids attach (bind) to the receptors, the interaction triggers a series of chemical changes within and between neurons that lead to feelings of pleasure and pain relief.
Normal function
ال OPRM1 gene provides instructions for making a protein called the mu (μ) opioid receptor. Opioid receptors are part of the endogenous opioid system, which is the body's internal system for regulating pain, reward, and addictive behaviors. It consists of opioid substances produced naturally within the body (called endogenous opioids) and their receptors, into which opioids fit like keys into locks. Opioid receptors are found in the nervous system, where they are embedded in the outer membrane of nerve cells (neurons). When opioids attach (bind) to the receptors, the interaction triggers a series of chemical changes within and between neurons that lead to feelings of pleasure and pain relief.
The μ opioid receptor was the first opioid receptor to be discovered. It is the primary receptor for endogenous opioids called beta-endorphin and enkephalins, which help regulate the body's response to pain, among other functions. The μ opioid receptor is also the binding site for many opioids introduced from outside the body (called exogenous opioids). These include commonly prescribed pain medications such as oxycodone, fentanyl, buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine, as well as illegal opioid drugs such as heroin.
When endogenous or exogenous opioids bind to the μ opioid receptor, the interaction triggers a cascade of chemical signals in the nervous system. These signals reduce the activity (excitability) of neurons in certain areas of the brain, which leads to pain relief and feelings of pleasure and intense happiness (euphoria). In addition, the chemical signaling ultimately increases the production of a chemical called dopamine. Dopamine is a chemical messenger (neurotransmitter) that helps regulate areas of the brain involved in reward-seeking behaviour, attention, and mood.
Conditions referring to this gene or chromosome
Other names
LMOR
M-OR-1
MOP
MOR
MOR-1
MOR1
mu opiate receptor
mu opioid receptor hMOR-1a
OPRM
Related patient information and medicines
Patient information leaflet
مسكنات الألم
There are three main types of painkiller: non-steroidal anti-inflammatory drugs (NSAIDS), paracetamol and opioids. Each works in a different way. ... However, it does not help with inflammation. المواد الأفيونية work by binding to certain receptors (opioid receptors) in the central nervous system, the gut and other parts of the body. This leads to a.
Patient information leaflet
هل يمكنني تناول المورفين والباراسيتامول معًا؟
Paracetamol and morphine have different 'mechanisms of action' (the way they work in the body). Paracetamol works mainly in the central nervous system to reduce pain signals, while morphine attaches to specific 'opioid receptors' to block pain. Because they don't interfere with each other's absorption or breakdown in the liver, they can be used.
Patient information leaflet
هل يمكنني تناول الكوديين والمورفين معًا؟
Taking codeine and morphine together significantly increases the risk of serious side effects, including extreme sleepiness, dizziness, and dangerous breathing problems. Because both drugs are strong painkillers from the same family (opioids), they 'stack' on top of each other, which can lead to an accidental overdose. Why this happens Both.
Patient information leaflet
مسكنات الألم القوية
Opioids are strong painkillers - medicines used to treat severe pain. How do opioids work. المواد الأفيونية work by attaching إلى opioid receptors in the brain و الورم الدموي فوق الجافية الفقري cord, the gut and other parts of the body. This leads to a decrease in the amount of pain felt. The National Institute for Health and Clinical Excellence (NICE) published guidance in 2021.
Patient information leaflet
الألم العضلي الليفي
The word فيبروميالغيا means pain (-algia) coming from the muscles (my-) and fibrous tissues (fibro-) such as tendons and ligaments. The risks of many medications outweigh their potential benefits, and opioid medications should be avoided due to the high risk of addiction and lack of long-term effectiveness. This is described in mo... In 2021, the.
Patient information leaflet
داء الخلايا البدينة واضطرابات الخلايا البدينة
Mast cells يكون hard-working cells that have many functions, including helping to fight infection. However, mast cell disorders can occur in which too many cells are produced or they become overactive. What are the types of mast cell disorder. Mastocytosis This is the te... Infection with germs (bacteria), funguses or viruses. Alcohol. Medicines -.
قراءة إضافية ومراجع
- opioid receptor mu 1; MedlinePlus, National Library of Medicine.
- Bonenberger M, Plener PL, Groschwitz RC, Gron G, Abler B. Polymorphism in the micro-opioid receptor gene (OPRM1) modulates neural processing of physical pain, social rejection and error processing. Exp Brain Res. 2015 Sep;233(9):2517-26. doi: 10.1007/s00221-015-4322-9. Epub 2015 May 28.
- Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav. 2014 Aug;123:25-33. doi: 10.1016/j.pbb.2013.10.018. Epub 2013 Nov 5.
- Davis C, Zai C, Levitan RD, Kaplan AS, Carter JC, Reid-Westoby C, Curtis C, Wight K, Kennedy JL. Opiates, overeating and obesity: a psychogenetic analysis. Int J Obes (Lond). 2011 Oct;35(10):1347-54. doi: 10.1038/ijo.2010.276. Epub 2011 Jan 25.
- Garriock HA, Tanowitz M, Kraft JB, Dang VC, Peters EJ, Jenkins GD, Reinalda MS, McGrath PJ, von Zastrow M, Slager SL, Hamilton SP. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry. 2010 May;167(5):565-73. doi: 10.1176/appi.ajp.2009.08081167. Epub 2010 Mar 1.
- Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics. 2013 May;14(7):813-24. doi: 10.2217/pgs.13.57.
- Pasternak G, Pan YX. Mu opioid receptors in pain management. Acta Anaesthesiol Taiwan. 2011 Mar;49(1):21-5. doi: 10.1016/j.aat.2010.12.008. Epub 2011 Mar 17.
- Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013 Sep 27;65(4):1257-317. doi: 10.1124/pr.112.007138. Print 2013.
- Reed B, Butelman ER, Yuferov V, Randesi M, Kreek MJ. Genetics of opiate addiction. Curr Psychiatry Rep. 2014 Nov;16(11):504. doi: 10.1007/s11920-014-0504-6.
- Schwantes-An TH, Zhang J, Chen LS, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Latvala A, Legrand LN, Maher BS, Melroy WE, Nelson EC, Reid MW, Robinson JD, Shen PH, Yang BZ, Andrews JA, Aveyard P, Beltcheva O, Brown SA, Cannon DS, Cichon S, Corley RP, Dahmen N, Degenhardt L, Foroud T, Gaebel W, Giegling I, Glatt SJ, Grucza RA, Hardin J, Hartmann AM, Heath AC, Herms S, Hodgkinson CA, Hoffmann P, Hops H, Huizinga D, Ising M, Johnson EO, Johnstone E, Kaneva RP, Kendler KS, Kiefer F, Kranzler HR, Krauter KS, Levran O, Lucae S, Lynskey MT, Maier W, Mann K, Martin NG, Mattheisen M, Montgomery GW, Muller-Myhsok B, Murphy MF, Neale MC, Nikolov MA, Nishita D, Nothen MM, Nurnberger J, Partonen T, Pergadia ML, Reynolds M, Ridinger M, Rose RJ, Rouvinen-Lagerstrom N, Scherbaum N, Schmal C, Soyka M, Stallings MC, Steffens M, Treutlein J, Tsuang M, Wall TL, Wodarz N, Yuferov V, Zill P, Bergen AW, Chen J, Cinciripini PM, Edenberg HJ, Ehringer MA, Ferrell RE, Gelernter J, Goldman D, Hewitt JK, Hopfer CJ, Iacono WG, Kaprio J, Kreek MJ, Kremensky IM, Madden PA, McGue M, Munafo MR, Philibert RA, Rietschel M, Roy A, Rujescu D, Saarikoski ST, Swan GE, Todorov AA, Vanyukov MM, Weiss RB, Bierut LJ, Saccone NL. Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behav Genet. 2016 Mar;46(2):151-69. doi: 10.1007/s10519-015-9737-3. Epub 2015 Sep 21.
- Walter C, Doehring A, Oertel BG, Lotsch J. micro-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. Pharmacogenomics. 2013 Nov;14(15):1915-25. doi: 10.2217/pgs.13.187.
- Xu J, Lu Z, Xu M, Pan L, Deng Y, Xie X, Liu H, Ding S, Hurd YL, Pasternak GW, Klein RJ, Cartegni L, Zhou W, Pan YX. A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the mu opioid receptor gene OPRM1 via hnRNPH interactions. J Neurosci. 2014 Aug 13;34(33):11048-66. doi: 10.1523/JNEUROSCI.3986-13.2014.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
6 Sept 2023 | أحدث إصدار
1 Nov 2017 | نُشر في الأصل
انضم إلى المحادثة
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اسأل، شارك، تواصل.
تصفح المناقشات، اطرح الأسئلة، وشارك التجارب عبر مئات المواضيع الصحية.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.